Pharmaceuticals, Biotechnology and Life Sciences
OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025 NANTES, France, September…
Analysis of the FAERS database shows that the real-world abuse potential of the DORA class is very low and markedly…
DALLAS, Sept. 08, 2025 (GLOBE NEWSWIRE) — BioNTX proudly announces that John Crowley, President and CEO of the Biotechnology Innovation…
PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung…
NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company…
SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…
Chemotherapy-free combination regimen has the potential to usher in new era for first-line treatment, with median overall survival projected to…
– 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal reference range within 5…
No-cost access available to qualified researchers via open-source federated data platformSAN FRANCISCO, Sept. 06, 2025 (GLOBE NEWSWIRE) — 23andMe Research…
New data demonstrate amivantamab combination significantly reduces common EGFR and MET resistance mutations seen with EGFR TKIs1 BEERSE, BELGIUM ,…